SEARCH

SEARCH BY CITATION

References

  • 1
    Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85: 2485-2502.
  • 2
    Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer E, et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A 2007; 104: 12884-12889.
  • 3
    Tellinghuisen TL, Foss KL, Treadaway JC, Rice CM. Identification of residues required for RNA replication in domain II and III of the hepatitis C virus NS5A protein. J Virol 2008; 82: 1073-1083.
  • 4
    Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical efficacy. Nature 2010; 465: 96-100.
  • 5
    Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the HCV NS5A inhibitor, BMS-790052, in the in vitro replicon system. Antimicrob Agents Chemother 2010; 54: 3641-3650.
  • 6
    Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury T, et al. Multiple-ascending dose study to evaluate BMS-790052, a novel NS5A inhibitor, in patients infected with hepatitis C virus genotype 1. Submitted to HEPATOLOGY.
  • 7
    Kieffer TL, Sarrazin C, Miller JS, Welker MS, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild type and resistance genotype 1 hepatitis C virus replication in patients. HEPATOLOGY 2007; 46: 631-639.
  • 8
    Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65: 202-212.
  • 9
    Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2009; 138: 446-462.
  • 10
    Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65: 202-212.
  • 11
    Lemm JA, O'Boyle DR, II, Liu M, Nower PT, Colonno R, Deshpande MS, et al. Identification of NS5A inhibitors. J Virol 2010; 84: 482-491.
  • 12
    Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777.
  • 13
    Villano S, Howe A, Raible D, Harper D, Speth J, Bichier G, et al. Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment naïve HCV-infected patients [Abstract 1127]. HEPATOLOGY 2006; 44( Suppl.): 607A-608A.